Evidence map›Paper›PMID 40398419›Full record

ArticleAmerican journal of human genetics2025

Identifying active and inhibitor-resistant MGMT variants for gene therapy.

Ana Cheong, Adam Fisher, Ashvin Bashyam, Anthony Forget, Robert Peters, Zachary David Nagel

Abstract read
In one paragraph

Article in American journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana CheongDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Adam FisherEnsoma Inc., Boston, MA 02210, USA.
Ashvin BashyamEnsoma Inc., Boston, MA 02210, USA.
Anthony ForgetEnsoma Inc., Boston, MA 02210, USA.
Robert PetersEnsoma Inc., Boston, MA 02210, USA.
Zachary David NagelDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: znagel@hsph.harvard.edu.

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI John A. Tainer · 2001 to 2026
$89.6M
NCI NIH HHS P01 CA092584
6 · The paper itself

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) reverses alkylating-agent-induced methylation by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) at the O

Indexed as

DNA Modification MethylasesDNA Repair EnzymesGenetic TherapyTumor Suppressor ProteinsCarmustineCell Line, TumorDrug Resistance, NeoplasmGuanineHumansCarmustineDNA Modification MethylasesDNA Repair EnzymesGuanineMGMT protein, humanO(6)-benzylguanineTumor Suppressor ProteinsDNA repairFM-HCRfunctional screengene therapyHSC therapyMGMT variantsO6-benzylguanineO6-methylguanine-DNA methyltransferaseP140KPaTrin-2

Identifiers

PMID40398419
PMCPMC12256902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.